GlassScriptPhysician profile
Minerva Medrano De Ramirez
NPI 1528474319
$3,856.92
in general payments reported to CMS, 2019-2025
21 companies · $762 in 2025
The $762 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $316 · 2022: $1,195 · 2023: $975 · 2024: $609 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,346.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $845.23 | 2021-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $629.35 | 2021-2025 | Ozempic, Wegovy |
| Lilly USA, LLC | $565.50 | 2021-2025 | Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $254.83 | 2022-2024 | |
| Angiodynamics, INC. | $252.51 | 2023-2025 | Auryon Laser System 100-120 Vac |
| Madrigal Pharmaceuticals | $230.15 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $143.43 | 2022-2023 | Xifaxan |
| Insulet Corporation | $140.12 | 2023 | Omnipod |
| Abbvie INC. | $124.99 | 2023 | |
| Janssen Pharmaceuticals, INC | $124.84 | 2024 | Xarelto |
| Glaxosmithkline, LLC. | $121.83 | 2025 | Benlysta |
| Abiomed | $86.99 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.72 | 2022-2024 | Jardiance |
| Edwards Lifesciences Corporation | $73.87 | 2022 | |
| Inspire Medical Systems, INC. | $68.84 | 2023 | Inspire |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $25.94 | 2022 | |
| Organon LLC | $24.84 | 2021-2022 | |
| Allergan, INC. | $20.69 | 2022 | |
| Myriad Women'S Health, INC. | $16.90 | 2023 | Myrisk |
| Abbott Laboratories | $16.89 | 2024 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $13.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minerva Medrano De Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.